Assay Development and Screening

Utilising the power of NGS and Genomics in screening

Wednesday, February 7
1:30 PM - 3:30 PM
Location: 6C

David R. Piper

Research and Development, Director
Thermo Fisher Scientific

David Piper has led teams at Thermo Fisher Scientific for over 10 years in the development of products and services for cellular engineering, biochemical assays and cell-based assays for the screening of multiple target classes (ion channels, GPCRs, kinases, nuclear receptors, pathway profiling) and next generation solutions for drug discovery using iPSC-based approaches. These efforts are directed at generating more patho-physiologically relevant cell models through the use of reprogramming, stem cell culture, characterization and differentiation, genomic engineering and assay development. Currently, as an R&D Director for the Cell Biology and Synthetic Biology businesses, he leads teams that provide molecular biology and cellular biology services including cDNA Library synthesis, high-throughput cloning, CRISPR and TALN design and generation, LENTI virus generation, BacMam virus generation, cell engineering (multiple delivery and integration platforms), assay development (multiple detection formats) and siRNA screening; often collaborating with GeneArt® gene synthesis and SelectScreen™ high-throughput screening services.


Send Email for David Piper


Utilising the power of NGS and Genomics in screening

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Utilising the power of NGS and Genomics in screening